Business Context and Reporting Period
This Form 8-K is filed by Pro-Pharmaceuticals, Inc. (noted as Galectin Therapeutics Inc. in metadata) for the reporting period of November 9, 2007. The filing discloses the entry into a material definitive agreement and the unregistered sale of equity securities in connection with a private placement.
Key Financial Metrics and Transaction Details
- Capital Raised: $100,000.
- Securities Issued: 100,000 Units sold to James C. Czirr.
- Price per Unit: $1.00.
- Unit Composition:
- One share of Series A 12% Convertible Preferred Stock.
- One Common Stock Purchase Warrant (exercise price: $1.50).
- One Common Stock Purchase Warrant (exercise price: $2.00).
- Preferred Stock Interest: 12% per annum, payable in cash or common stock at the company's option.
- Warrant Terms: Exercisable for cash beginning 181 days after issuance and until the fourth anniversary.
Material Changes and Agreements
The company entered into a Securities Purchase Agreement and a Registration Rights Agreement. Under the Registration Rights Agreement, the company agreed to file a registration statement with the SEC within six months of the offering's closing to register the resale of common stock issuable upon conversion of the Preferred Stock and exercise of the warrants. The transaction was exempt from registration under Section 4(2) of the Securities Act of 1933.
Outlook, Risks, and Contingencies
- Conversion Rights: Preferred Stock is convertible at the holder's option into one share of Common Stock. The company retains the right to require mandatory conversion if the Common Stock closing price exceeds $3.00 for 15 consecutive trading days and a registration statement is in effect.
- Adjustments: Exercise prices and conversion ratios are subject to adjustment in the event of stock splits, reorganizations, or mergers.
- Financial Statements: No pro forma financial information or financial statements of acquired businesses were provided in this filing.
Investor Verification Checklist
- Verify the filing of the registration statement for resale of securities within the required six-month window.
- Confirm the current status of the Series A Preferred Stock interest payments (cash vs. stock).
- Monitor the Common Stock price relative to the $3.00 threshold for potential mandatory conversion.
- Review the full text of Exhibits 10.1 through 10.4 for specific covenants and anti-dilution provisions.